New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy

Home > Science Hub > New Publication:
Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy
Back to the list

April 11, 2024

Hartmut Koeppen et al. The Journal of Pathology

Automated tumor immunophenotyping predicts clinical benefit from anti-PD-L1 immunotherapy

You might also be interested by

Webcasts & Webinars

Let's Talk: A Conversation with Dr. Scott Gottlieb

September 10, 2024

More info

CellTalk Blog

Optimal FFPE Tissue Fixation, Processing, and Embedding: A Comprehensive Guide

September 4, 2024

Histopathology

More info

CellTalk Blog

Optimizing your in situ hybridization for success

August 30, 2024

Histopathology

More info

News

Let’s Talk: A Conversation with Former FDA Commissioner Scott Gottlieb

August 14, 2024

More info